Amneal Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Amneal Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 9, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.79B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.39B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.21B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.09B | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $1.99B | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | $397.33M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $378.28M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $404.64M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $446.12M | Mar 2, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $820.57M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $784.71M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $768.97M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $628.39M | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | $110.23M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $54.43M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $105.25M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $83.08M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.06M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($116.89M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($83.99M) | Feb 27, 2026 |
| FY2023 | Dec 31, 2022 | ($270.58M) | Mar 14, 2024 |
| FY2023 | Dec 31, 2021 | $13.16M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $67.79M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($603.57M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($19.74M) | Mar 1, 2021 |
| FY2017 | Dec 31, 2017 | $0 | Mar 9, 2018 |
| FY2018 | Dec 31, 2016 | $0 | Mar 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $394.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $249.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $204.37M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($94.93M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $152.72M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $91.16M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($248.68M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($19.67M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $245.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $284.88M | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.18M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $190.71M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $163.95M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $195.69M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $201.85M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $179.93M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $188.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $194.19M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $171.42M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $179.02M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $526.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $476.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $429.68M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $399.70M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $365.50M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $326.73M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $289.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $227.85M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $109.05M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $118.76M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.99M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $295.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $345.58M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $65.10M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $241.82M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $379.00M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $1.71M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $250.23M | Mar 1, 2021 |
| FY2017 | Dec 31, 2017 | $0 | Mar 9, 2018 |
| FY2018 | Dec 31, 2016 | $115.06M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.06M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $51.92M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $43.22M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $46.41M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $47.73M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $56.45M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $47.18M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $83.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $94.77M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $122.76M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.68B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.50B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.47B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.80B | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $3.94B | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $4.01B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $3.67B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $4.35B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.34B | Mar 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.79M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($109.27M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $19.78M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $298.42M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $360.34M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $303.27M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $232.01M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $504.75M | Mar 2, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Mar 9, 2018 |
| FY2017 | Oct 4, 2017 | $0 | Mar 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $595.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $597.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $598.63M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $598.85M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $593.02M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $522.81M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $419.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $426.23M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $26.44M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $28.44M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($535.01M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($607.06M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($490.18M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($406.18M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($276.20M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($286.82M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($377.88M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($20.92M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($382.79M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $282.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $110.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $91.54M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $25.98M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $247.79M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $341.38M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $151.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $213.39M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $74.17M | Mar 2, 2020 |
| FY2017 | Oct 4, 2017 | $0 | Mar 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.39B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.42B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.62B | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.71B | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.78B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.63B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $2.65B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.44B | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | (2) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | (2) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | 1,000 | Mar 9, 2018 |